James Peyer: Geroscience evidence is the key to unlocking preventative therapies
As the world gears up for the fourth annual Longevity Leaders World Congress, Cambrian Biopharma’s CEO James Peyer looks through the therapeutic window.
In the?first part of our interview with James Peyer, he described?Cambrian's stepping stone approach to drug discovery and development, but says the challenges encountered in geroscience research are not what one might initially expect.
My take on this: When it comes to discovering great science that can be turned into drugs that could reach safety and efficacy milestones, although the hard work should not be underestimated, this is not a challenge?per se – rather it is the journey from discovery to prevention, not just treatment, that proves more tricky.
“This dance from stepping stone to prevention is is something that no drug development organisation has ever pulled off particularly well,” explains Peyer.
“The identification of potential drugs is going incredibly well for Cambrian, and we have a great team of drug developers that are making a set of significant drugs. The tough part is figuring out how can we move into the prevention space as quickly as possible in a way that makes sense from a risk perspective and from an FDA regulatory perspective.”
Thanks for reading! If you’ve enjoyed this article, it would mean a lot to me if you could subscribe and share it on LinkedIn!
Mediziner & Lebenswissenschaftler | Entwicklung von Gesundheitsl?sungen | Wissenschaftskommunikation
2 年Phil Newman - after two decades of my own nutrition research and setting up nutrition interventions for the prevention of chronic diseases, I had a dejavue when I read this quote from the interview with James Peyer: “Of course, it’s hard to demonstrate an intervention is preventing something from happening, although we’re working on it –it takes a lot of time, a lot of data and a lot of careful thought!”